1,598 karma · joined November 11, 2014
"Long-term follow-up of the UK Age RCT" "There was a statistically significant 25% reduction in mortality from breast cancers diagnosed during the intervention phase at 10 years' follow-up"
For CT vs. XRay there have already been 2 long term randomized controlled trials that look at outcomes for lung cancer screening. PLCO, the XRay study, was not effective in improving long term outcomes like mortality. NLST, the CT study, showed a 20% reduction in mortality. With more modern techniques that actually look at the tumor in 3D NELSON in Europe has seen even better mortality reduction.
DBT is newer so A) Radiologists are not as good at reading it yet B) the long term evidence hasn't accumulated yet, but I am definitely optimistic that it will present a big improvement over the previous state of the art.
As mentioned elsewhere in the thread, this false positive number is already better than the existing state of the art for 2D.
I am most familiar with NLST which actually was a long term randomized trial.
However, in my opinion, there has been a systemic resistance to screening because of statistics like this, and that is misguided. This is not the right number to use for determining whether or not screening is useful.
A 3D mammogram will have false positives, yes. And some women will need to either get an uneccesary ultrasound (annoying, but not harmful) or worse, an uneccessary tissue sample (biopsy). This type of biopsy is done with a needle and is certainly uncomfortable, but carries little to no risk. This is all true. But it needs to be balanced against the fact that catching cancer early gives you an immensely better chance of surviving.
The right numbers to look at are more like: How much does a screening program reduce overall mortality rates? How much does the screening program reduce breast cancer mortality rate? What are the impacts of this in terms of QALY (quality adjusted life years)? What are the impacts of the false positives in quality adjusted life years?
I believe on balance the answer to these questions is that screening for breast cancer is on the whole beneficial. Here is one example study https://pubmed.ncbi.nlm.nih.gov/31098856/
Now the question is, how will 3D affect these questions? That is as of yet unanswered as far as I know but we shouldn't let numbers like this influence the conversation prematurely.
(edit yes of course cancer is not beneficial thank you)
Would be a sad but hilarious example of why lab bench testing and testing in humans or animals is such a large gap
Bench: The worms swim towards the cancer cells on this 3 inch, 2D glass media!
Animal trial in mice: The worms swim towards the cancer cells!
Humans: Oh shit the worms are totally lost in this huge space. Also the patient has a lot of worms in their lungs.
NYTimes headline
“Google abusing monopoly position to muscle out delivery startups”
How would Google know which postings are fraudulent and which aren't? The vast majority of these postings are fine/legitimate/consented. Why does it have to be Google that spends time and energy going after the bad actors, and if they don't, they become one?
In other words, I really don't see how Google is in the best position to figure out which restaurants have been posted without the restaurant's consent. I think that would be the companies putting up the original post.
In addition, the R of crud is hard to combine with vector indices. Case in point I am still waiting for elastic search to support both ANN and regular, structured filtering together well.
Do you think the senate would still have certified the election? Or would Trump still be president?
I think the fear is that the mob was almost able to make it so that Trump’s lie about a stolen election would have overridden the democratic process.
If such an event happened, it would have been fair to say that event “killed democracy”
Obviously we shouldn’t just exactly copy the system of other countries, but it’s equally shortsighted to not learn take away anything from other existing systems. The possibility for universal coverage and higher cost efficiency without the need for single payer I think is a valid thing to take away from those examples.
Japanese system does have a public option and much tighter price controls, which we are missing here.